Clinicopathologic characteristics and outcomes of transformed diffuse large <scp>B</scp>‐cell lymphoma in hepatitis <scp>C</scp> virus‐infected patients

Jeff Hosry(The University of Texas MD Anderson Cancer Center), Harrys A. Torres(The University of Texas MD Anderson Cancer Center), Roberto N. Miranda(The University of Texas MD Anderson Cancer Center), Felipe Samaniego(The University of Texas MD Anderson Cancer Center), Minas P. Economides(NYU Langone Health)

International Journal of Cancer

October 19, 2017

10.1002/ijc.31110

Cited by 14

Related Papers

MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program

|Blood|2013|677

Characteristics of anti-CD19 CAR T cell infusion products associated with efficacy and toxicity in patients with large B cell lymphomas

|Nature Medicine|2020|593

Complete Surgical Excision Is Essential for the Management of Patients With Breast Implant–Associated Anaplastic Large-Cell Lymphoma

|Journal of Clinical Oncology|2015|418

Mutational profile and prognostic significance of TP53 in diffuse large B-cell lymphoma patients treated with R-CHOP: report from an International DLBCL Rituximab-CHOP Consortium Program Study

|Blood|2012|390

Double hit lymphoma: the <scp>MD A</scp> nderson <scp>C</scp> ancer <scp>C</scp> enter clinical experience

|British Journal of Haematology|2014|364